Edition:
United Kingdom

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

5.80USD
16 Feb 2018
Change (% chg)

$0.15 (+2.65%)
Prev Close
$5.65
Open
$5.60
Day's High
$5.90
Day's Low
$5.55
Volume
15,142
Avg. Vol
10,446
52-wk High
$6.75
52-wk Low
$2.45

Chart for

About

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is... (more)

Overall

Beta: --
Market Cap(Mil.): $55.33
Shares Outstanding(Mil.): 14.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-KemPharm posts Q3 loss per share $0.68

* KemPharm reports third quarter 2017 results and provides corporate update

09 Nov 2017

BRIEF-KemPharm receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511

* KemPharm Inc receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511 Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-KemPharm says KP484 allowed to proceed to clinical studies​

* kempharm’s kp484 for the treatment of adhd, an investigational prodrug of methylphenidate, allowed to proceed to clinical studies

02 Nov 2017

BRIEF-KemPharm files IND application for KP484 for the treatment of ADHD

* KemPharm files IND for KP484 for the treatment of ADHD, an investigational prodrug of methylphenidate

20 Sep 2017

Earnings vs. Estimates